Women diagnosed with DCIS face a threefold higher risk of breast cancer mortality. Learn the warning signs, treatment options ...

High-risk NMIBC is characterised by poor prognosis, with half of patients recurring despite effective treatment with the ...

Beyond five days’ of statutory sick pay a year, your employer is not obliged to keep paying you if you fall ill ...

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing ...

The FDA issued an RTF for sBLA of nogapendekin alfa plus BCG for BCG-unresponsive NMIBC papillary disease, following prior ...

Welcome to the Relmada Therapeutics first-quarter 2025 earnings call. (Operator Instructions) As a reminder, this conference is being recorded, and will be available for replay on the location website ...

You’ve probably heard of the four stages of cancer—but there’s another even earlier stage that experts say can make a huge ...

A biopsy reveals squamous cell carcinoma (SCC) in situ. What should be the next steps in the patient's evaluation and management? After the initial consultation, the patient's biopsy specimen was ...

An Update on QUILT 3.032: Complete Responses to N-803 plus BCG Therapy in BCG-Unresponsive Bladder Carcinoma in Situ (CIS) With or Without Ta/T1 Papillary Disease (PD12-12) Chang S. Oral Podium ...

The targeted drug release device TAR-200 shows promising response and disease-free survival rates in specific populations of ...

Stage 0, often called “carcinoma in situ”, is the earliest form of cancer. The Latin phrase in situ means “in its original ...

It is also known as carcinoma in situ. In papillary urothelial carcinoma, the cancer cells grow into the space of the bladder in shapes that are described as finger- or mushroom-like. Papillary ...